Angisan Grup S.R.L.
- Address
- Romania, Strada Florilor 7, 077025 Bragadiru, Romania
Angisan Grup S.R.L. - Respiratory Disease Research Center
Angisan Grup S.R.L. is a specialized clinical research center with demonstrated expertise in chronic respiratory diseases, particularly focusing on Chronic Obstructive Pulmonary Disease (COPD) and asthma. The center has extensive experience conducting phase 2 and phase 3 clinical trials evaluating novel therapeutic agents, including biologics and small molecules, for patients with moderate to severe respiratory conditions.
- COPD exacerbation prevention and long-term safety studies with biologics and novel add-on therapies to triple maintenance therapy
- Asthma control trials assessing rescue medications, maintenance therapies, and lung function preservation in uncontrolled moderate-to-severe disease
- Innovative inhaled corticosteroid combinations and fixed-dose triple therapy formulations for respiratory diseases
- Advanced respiratory pharmacology studies including novel propellant formulations and bronchodilator safety assessments
The center demonstrates particular strength in evaluating disease-modifying therapies and conducting long-term extension studies to assess safety and tolerability profiles. Their research portfolio includes trials with cutting-edge biologic agents such as itepekimab, verekitug, and dupilumab, as well as novel therapeutic compounds like tanimilast. Angisan Grup S.R.L. is well-equipped to conduct complex studies requiring precise lung function measurements, exacerbation rate assessments, and comprehensive safety monitoring in patients with chronic respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Chiesi Farmaceutici S.p.A.3active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.7trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Angisan Grup S.R.L.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 4 | Unknown | 2022-04-22 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.